title: Serum YKL-40 following resection for cerebral glioblastoma.
abstract: The lack of serum biomarkers for assessing the prognosis of patients with cerebral glioblastoma multiforme (GBM) prompted the present study in order to evaluate the significance of serum YKL-40 values in patients operated on for glioblastoma. An homogeneous population of 60 patients who underwent surgical removal of GBM underwent a standard treatment (surgery, radiotherapy, chemotherapy in the same schedule) and standard radiological monitoring (same MRI sequences at pre-defined stages). Serum YKL-40 levels (Quidel Corporation, San Diego, CA) were evaluated after dividing patients into two groups on the basis of the extent of resection (total or sub-total) according to the MRI results obtained within 48 h following surgery. YKL-40 serum values, significantly higher in GBM patients than in healthy subjects, were also higher among patients who had undergone subtotal resection than in patients who underwent extensive resection. The effect of YKL-40 on overall survival was analyzed by comparing the change in marker concentration occurring in the first postoperative week with the baseline value. A significant (P = 0.04) hazards ratio of 1.97 was found at multivariate analysis. A significant association with shorter outcome (median survival time, 76 days) was found in patients whose postoperative YKL-40 concentration increases higher than, or equal to, 100%; a 50% increase can still be considered a negative prognostic index. The evaluation of the biochemical marker YKL-40 might provide earlier and additional information to that obtained using traditional factors and be a further aid in establishing the prognosis of GBM patients who have undergone surgery.
authors.affiliation: Department of Laboratory Medicine, University-Hospital of Padova, Via Giustiniani, 2, 35128 Padova, Italy. daniela.bernardi@sanita.padova.it
authors.forename: Daniela
authors.initials: D
authors.lastname: Bernardi
authors.forename: Andrea
authors.initials: A
authors.lastname: Padoan
authors.forename: Andrea
authors.initials: A
authors.lastname: Ballin
authors.forename: Mariateresa
authors.initials: M
authors.lastname: Sartori
authors.forename: Renzo
authors.initials: R
authors.lastname: Manara
authors.forename: Renato
authors.initials: R
authors.lastname: Scienza
authors.forename: Mario
authors.initials: M
authors.lastname: Plebani
authors.forename: Alessandro
authors.initials: A
authors.lastname: Della Puppa
mesh_terms: D054392:Adipokines / Q000097:blood*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001932:Brain Neoplasms / Q000097:blood* / Q000401:mortality / Q000601:surgery*; D016009:Chi-Square Distribution; D000071451:Chitinase-3-Like Protein 1; D005260:Female; D005500:Follow-Up Studies; D005909:Glioblastoma / Q000097:blood* / Q000401:mortality / Q000601:surgery*; D006801:Humans; D007118:Immunoassay; D053208:Kaplan-Meier Estimate; D037102:Lectins / Q000097:blood*; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009493:Neurosurgery / Q000379:methods*
chemical_list: D054392:Adipokines; C084533:CHI3L1 protein, human; D000071451:Chitinase-3-Like Protein 1; D037102:Lectins
references.citation: Lancet Oncol. 2008 May;9(5):453-61
references.pmid: 18452856
references.citation: Clin Cancer Res. 2006 Oct 1;12(19):5698-704
references.pmid: 17020973
references.citation: Lung Cancer. 2004 Dec;46(3):333-40
references.pmid: 15541818
references.citation: Lung Cancer. 2005 May;48(2):223-31
references.pmid: 15829322
references.citation: BMC Cancer. 2009 Dec 18;9:450
references.pmid: 20017960
references.citation: Clin Cancer Res. 2005 Mar 15;11(6):2258-64
references.pmid: 15788675
references.citation: Scand J Clin Lab Invest. 2000 Jul;60(4):247-51
references.pmid: 10943594
references.citation: N Engl J Med. 2008 Jul 31;359(5):492-507
references.pmid: 18669428
references.citation: Cancer Lett. 2003 Aug 20;198(2):203-10
references.pmid: 12957359
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Neuro Oncol. 2006 Jan;8(1):38-46
references.pmid: 16443946
references.citation: Clin Cancer Res. 2005 May 1;11(9):3326-34
references.pmid: 15867231
references.citation: Breast Cancer Res Treat. 2003 Jul;80(1):15-21
references.pmid: 12889595
references.citation: Cancer Res. 2005 Mar 1;65(5):1678-86
references.pmid: 15753362
references.citation: Curr Opin Neurol. 2003 Dec;16(6):643-50
references.pmid: 14624071
references.citation: Clin Chem. 2010 Oct;56(10):1580-91
references.pmid: 20798353
references.citation: Cancer Res. 2002 Aug 1;62(15):4364-8
references.pmid: 12154041
references.citation: Arthritis Rheum. 1999 Dec;42(12):2624-30
references.pmid: 10616010